Edition:
United Kingdom

Immune Design Corp (IMDZ.OQ)

IMDZ.OQ on NASDAQ Stock Exchange Global Market

1.71USD
15 Oct 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$1.71
Open
$1.89
Day's High
$1.89
Day's Low
$1.70
Volume
138,833
Avg. Vol
45,463
52-wk High
$11.05
52-wk Low
$1.48

Latest Key Developments (Source: Significant Developments)

Immune Design Q2 Loss Per Share $0.29
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Immune Design Corp ::IMMUNE DESIGN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.29.Q2 REVENUE $800,000.Q2 REVENUE VIEW $1.3 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.30 -- THOMSON REUTERS I/B/E/S.  Full Article

Immune Design Reports Data Update For Lead Immunotherapy Programs
Monday, 12 Mar 2018 

March 12 (Reuters) - Immune Design Corp ::IMMUNE DESIGN REPORTS DATA UPDATE FOR LEAD IMMUNOTHERAPY PROGRAMS: IMPROVEMENT IN SURVIVAL FOR CMB305 MONOTHERAPY IN SARCOMA AND INCREASED OBJECTIVE RESPONSES FOR G100/PEMBROLIZUMAB COMBINATION IN FOLLICULAR LYMPHOMA.IMMUNE DESIGN CORP - ‍CMB305 CONTINUES TO BE WELL TOLERATED, WITH ONLY ONE GRADE 3 ADVERSE EVENT​.IMMUNE DESIGN CORP - ‍MEDIAN OVERALL SURVIVAL ACROSS ALL STS PATIENTS HAS BEEN REACHED AT 23.7 MONTHS FROM CMB305 MONOTHERAPY TRIAL​.  Full Article

Ecor1 Capital reports 7.4% passive stake in Immune Design
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Ecor1 Capital Llc::Ecor1 Capital Llc reports 7.4% passive stake in Immune Design Corp as of Oct 25 - SEC filing‍​.  Full Article

Immune Design reports Q3 loss per share of $0.52
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Immune Design Corp -:IMMUNE DESIGN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.52.Q3 REVENUE $500,000.Q3 REVENUE VIEW $1.4 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.  Full Article

Immune Design prices offering of 19.5 million shares at $4.10 per share​
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Immune Design Corp :Immune Design prices $80.0 million public offering of common stock.Says ‍priced public offering of 19.5 million shares of its common stock at price to public of $4.10 per share​.  Full Article

Immune Design proposes public offering of common stock
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Immune Design Corp :Immune Design announces proposed public offering of common stock.Immune Design Corp - ‍plans to offer and sell up to 16 million shares of its common stock in an underwritten public offering​.Immune Design Corp - ‍net proceeds of offering to fund its Phase 3 clinical trial for CMB305 in synovial sarcoma patients & to continue to develop CA21.  Full Article

Immune Design gets positive FDA feedback on Phase 3 clinical trial design for CMB305
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Immune Design Corp :Immune Design announces positive FDA feedback on Phase 3 clinical trial design for CMB305 in synovial sarcoma patients.Immune Design- plans to initiate pivotal Phase 3 trial to support a Biologics License Application (BLA) for CMB305 in patients with synovial sarcoma​.  Full Article

Bain Capital Public Equity Management LLC reports a 5.07 pct passive stake in Immune Design
Friday, 6 Oct 2017 

Oct 6 (Reuters) - Immune Design Corp :Bain Capital Public Equity Management LLC reports a 5.07 percent passive stake in Immune Design Corp as of September 29, 2017 - SEC Filing‍​.  Full Article

Immune Design says it may offer shares of up to $50 mln
Monday, 3 Jul 2017 

July 3 (Reuters) - Immune Design Corp :Immune design corp - ‍immune design corp. Entered into a sales agreement with cowen and company, llc​.Immune design corp - ‍co may offer and sell shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $50 million​.Immune design corp - co may offer and sell, from time to time at its sole discretion through cowen, as its sales agent, shares of its common stock​.  Full Article

BRIEF-Immune Design Q1 Loss Per Share $0.28

* IMMUNE DESIGN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE